{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:28:28Z","timestamp":1790011708194,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["IUMS\/SHMIS-98-4-37-16709"],"award-info":[{"award-number":["IUMS\/SHMIS-98-4-37-16709"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>About 5\u201310% of breast cancer cases are attributed to a gene mutation. To perform preventive interventions for women with a gene mutation, genetic screening BRCA tests have recently been implemented in Iran. The present study aimed to determine Iranian women\u2019s subjective valuation for screening BRCA tests for early detection of breast cancer to help policymakers to make decisions about genetic screening tests for breast cancer and to know the applicants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An online survey was completed by women older than 30 years old in Tehran, the capital of Iran in 2021. A hypothetical scenario about genetic screening tests for breast cancer was defined. The subjective valuation for the tests was assessed by a willingness to pay (WTP) using the contingent valuation method (CVM) by payment card. Demographics, history of breast cancers, knowledge, and physiological variables were considered as independent variables, and a logistic regression model assessed the relationship between WTP and the variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>660 women were included. 88% of participants intended to participate in BRCA genetic screening for breast cancer if it were free. The mean WTP for the tests was about $ 20. Based on the logistic regression, income, family history of breast or ovarian cancer, and positive attitude were associated with WTP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Iranian women were willing to intend for genetic screening BRCA tests and pay for them as well. The result of the present study is of great importance for policy makers when it comes to funding and determining co-payments for BRCA genetic screening tests. To achieve a high participation rate of women in breast cancer screening plans, a positive attitude should be promoted as a psychological factor. Educational and informative programs can help.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-023-15568-0","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T09:03:23Z","timestamp":1681203803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Subjective valuation of Iranian women for screening for gene-related diseases: a case of breast cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Zahra","family":"Meshkani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmeh","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aboutorabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdosaleh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshanak","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"01","key":"15568_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CM9.0000000000001814","volume":"135","author":"C Luo","year":"2022","unstructured":"Luo C, et al. Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019. Chin Med J. 2022;135(01):42\u201351.","journal-title":"Chin Med J"},{"issue":"1","key":"15568_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40944-022-00613-4","volume":"20","author":"M Kazeminia","year":"2022","unstructured":"Kazeminia M, et al. The prevalence of breast cancer in iranian women: a systematic review and meta-analysis. Indian J Gynecologic Oncol. 2022;20(1):14.","journal-title":"Indian J Gynecologic Oncol"},{"key":"15568_CR3","unstructured":"International Agency for Research on Cancerhttps:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/20-Breast-fact-sheet.pdf 2020."},{"issue":"1","key":"15568_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/pharmaceutics11010022","volume":"11","author":"CO Silva","year":"2019","unstructured":"Silva CO, et al. Current trends in cancer nanotheranostics: metallic, polymeric, and lipid-based systems. Pharmaceutics. 2019;11(1):22.","journal-title":"Pharmaceutics"},{"issue":"1","key":"15568_CR5","first-page":"71","volume":"3","author":"H Khaleghi Mahani","year":"2017","unstructured":"Khaleghi Mahani H, et al. Breast self\u2013examination predictors based on Precede Model: a study on female active health volunteers in Zarand City. J Health Based Res. 2017;3(1):71\u201385.","journal-title":"J Health Based Res"},{"key":"15568_CR6","unstructured":"Noori MR. D., Molecular genetics, diagnosis and treatment of breast cancer.review article. j Sabzevar Univ Med Sci 2010;172(56):74\u201387"},{"issue":"4","key":"15568_CR7","first-page":"579","volume":"46","author":"AA Valipour","year":"2017","unstructured":"Valipour AA, et al. Predict the future incidence and mortality of breast cancer in Iran from 2012\u20132035. Iran J public health. 2017;46(4):579\u201380.","journal-title":"Iran J public health"},{"issue":"11","key":"15568_CR8","doi-asserted-by":"publisher","first-page":"e0207993","DOI":"10.1371\/journal.pone.0207993","volume":"13","author":"L Sun","year":"2018","unstructured":"Sun L, et al. Global treatment costs of breast cancer by stage: a systematic review. PLoS ONE. 2018;13(11):e0207993.","journal-title":"PLoS ONE"},{"issue":"9","key":"15568_CR9","first-page":"1225","volume":"44","author":"R Daroudi","year":"2015","unstructured":"Daroudi R, et al. The economic burden of breast cancer in Iran. Iran J public health. 2015;44(9):1225.","journal-title":"Iran J public health"},{"issue":"10","key":"15568_CR10","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.11124\/JBIES-20-00402","volume":"19","author":"P Erfani","year":"2021","unstructured":"Erfani P, et al. Cost of breast cancer care in low- and middle-income countries: a scoping review protocol. JBI Evid Synthesis. 2021;19(10):2813\u201328.","journal-title":"JBI Evid Synthesis"},{"issue":"2","key":"15568_CR11","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1200\/OP.20.00571","volume":"17","author":"J Armstrong","year":"2021","unstructured":"Armstrong J, et al. Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study. JCO Oncol Pract. 2021;17(2):e226\u201335.","journal-title":"JCO Oncol Pract"},{"key":"15568_CR12","doi-asserted-by":"publisher","first-page":"S454","DOI":"10.1016\/j.jval.2019.09.292","volume":"22","author":"H Tuffaha","year":"2019","unstructured":"Tuffaha H, Scuffham P. PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies. Value in Health. 2019;22:S454.","journal-title":"Value in Health"},{"issue":"24","key":"15568_CR13","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.1158\/1078-0432.CCR-08-1211","volume":"14","author":"OI Olopade","year":"2008","unstructured":"Olopade OI, et al. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14(24):7988\u201399.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15568_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-006-9270-4","volume":"101","author":"H Yasunaga","year":"2007","unstructured":"Yasunaga H, et al. Women\u2019s anxieties caused by false positives in mammography screening: a contingent valuation survey. Breast Cancer Res Treat. 2007;101(1):59\u201364.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"15568_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/jgc4.1356","volume":"30","author":"D Cragun","year":"2021","unstructured":"Cragun D, et al. Family communication of genetic test results among women with inherited breast cancer genes. J Genet Couns. 2021;30(3):701\u20139.","journal-title":"J Genet Couns"},{"issue":"1","key":"15568_CR16","first-page":"49","volume":"12","author":"S Hajian","year":"2011","unstructured":"Hajian S, et al. Effects of education based on the health belief model on screening behavior in high risk women for breast cancer, Tehran, Iran. Asian Pac J Cancer Prev. 2011;12(1):49\u201354.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"15568_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.30699\/ijbd.15.2.4","volume":"15","author":"S Haghighat","year":"2022","unstructured":"Haghighat S, Omidi Z, Ghanbari-Motlag A. Trend of breast cancer incidence in Iran a fifteen year interval according to national cancer registry report. Iran J breast disease. 2022;15(2):4\u201317.","journal-title":"Iran J breast disease"},{"issue":"4","key":"15568_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1017\/S1049023X21000649","volume":"36","author":"SJ Stratton","year":"2021","unstructured":"Stratton SJ. Population research: convenience sampling strategies. Prehosp Disaster Med. 2021;36(4):373\u20134.","journal-title":"Prehosp Disaster Med"},{"key":"15568_CR19","doi-asserted-by":"crossref","unstructured":"Mitchell RC, Carson RT. Using surveys to value public goods: the contingent valuation method. Rff Press; 2013.","DOI":"10.4324\/9781315060569"},{"issue":"1","key":"15568_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/00048403208540952","volume":"10","author":"J Hull","year":"1932","unstructured":"Hull J. The subjective theory of value. Australasian J Psychol Philos. 1932;10(1):17\u201325.","journal-title":"Australasian J Psychol Philos"},{"issue":"6","key":"15568_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/1471-0528.15654","volume":"126","author":"R Manchanda","year":"2019","unstructured":"Manchanda R, et al. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi jewish population: a cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(6):784\u201394.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"issue":"12","key":"15568_CR22","first-page":"1579","volume":"11","author":"HS Thompson","year":"2002","unstructured":"Thompson HS, et al. Psychosocial predictors of BRCA counseling and testing decisions among urban african-american women. Cancer Epidemiol biomarkers Prev. 2002;11(12):1579\u201385.","journal-title":"Cancer Epidemiol biomarkers Prev"},{"issue":"3","key":"15568_CR23","first-page":"150","volume":"4","author":"AW Helmes","year":"2002","unstructured":"Helmes AW, Bowen DJ, Bengel J. Patient preferences of decision-making in the context of genetic testing for breast cancer risk. Genet Sci. 2002;4(3):150\u20137.","journal-title":"Genet Sci"},{"issue":"4","key":"15568_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1017\/S1930297500005180","volume":"10","author":"T Miron-Shatz","year":"2015","unstructured":"Miron-Shatz T, et al. Willingness to test for BRCA1\/2 in high risk women: influenced by risk perception and family experience, rather than by objective or subjective numeracy? Judgm Decis Mak. 2015;10(4):386\u201399.","journal-title":"Judgm Decis Mak"},{"issue":"2","key":"15568_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.pec.2004.02.007","volume":"56","author":"J Erblich","year":"2005","unstructured":"Erblich J, et al. Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns. 2005;56(2):182\u201391.","journal-title":"Patient Educ Couns"},{"issue":"6","key":"15568_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1006\/pmed.2001.0920","volume":"33","author":"AY Kinney","year":"2001","unstructured":"Kinney AY, et al. Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large african-american kindred with a BRCA1 mutation. Prev Med. 2001;33(6):543\u201351.","journal-title":"Prev Med"},{"issue":"1","key":"15568_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2193-1801-3-350","volume":"3","author":"D Lalla","year":"2014","unstructured":"Lalla D, et al. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. Springerplus. 2014;3(1):1\u20137.","journal-title":"Springerplus"},{"issue":"2","key":"15568_CR28","doi-asserted-by":"publisher","first-page":"e016662","DOI":"10.1136\/bmjopen-2017-016662","volume":"8","author":"J Blouin-Bougie","year":"2018","unstructured":"Blouin-Bougie J, et al. Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional web-based survey among women of Qu\u00e9bec (Canada). BMJ open. 2018;8(2):e016662.","journal-title":"BMJ open"},{"key":"15568_CR29","doi-asserted-by":"crossref","unstructured":"Wong XY et al. Women\u2019s preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment Patient preference and adherence, 2018: p.\u00a01837\u20131852.","DOI":"10.2147\/PPA.S171348"},{"issue":"11","key":"15568_CR30","first-page":"1251","volume":"9","author":"K Armstrong","year":"2000","unstructured":"Armstrong K, et al. Factors associated with decisions about clinical BRCA1\/2 testing. Cancer Epidemiol Prev Biomarkers. 2000;9(11):1251\u20134.","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"issue":"2","key":"15568_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1017\/S1930297500005519","volume":"9","author":"T Miron-Shatz","year":"2014","unstructured":"Miron-Shatz T, et al. Subjective but not objective numeracy influences willingness to pay for BRCA1\/2 genetic testing. Judgm Decis Mak. 2014;9(2):152\u20138.","journal-title":"Judgm Decis Mak"},{"issue":"1","key":"15568_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/gte.2006.9998","volume":"11","author":"B Godard","year":"2007","unstructured":"Godard B, et al. Factors associated with an individual\u2019s decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. Genet Test. 2007;11(1):45\u201354.","journal-title":"Genet Test"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15568-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T09:04:43Z","timestamp":1681203883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15568-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["15568"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15568-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"15 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that the experimental protocol and the study was approved by the ethics committee of Iran University of medical sciences.The authors confirm that all methods were performed following the relevant guidelines and regulations to this effect (Declaration of Helsinki).The authors confirmed that informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"667"}}